17 September 2026

ICG plc (the “Company”)

Transaction in Own Shares, Completion of Share Buyback Programme and Total Voting Rights

The Company announces that on 9 September 2026, in accordance with the terms of its share buyback programme announced on 19 February 2026 (the “Share Buyback”), the Company has purchased 72,916 ordinary shares of nominal value of £0.2625 each in the capital of the Company (the “Ordinary Shares“) on the London Stock Exchange through Merrill Lynch International (“BofA Securities”).

The Share Buyback is to enable the Company to issue Ordinary Non-Voting shares to Amundi equal to the number of Ordinary Shares repurchased by the Company in a manner that is non-dilutive to the Company’s existing shareholders in connection with its strategic partnership with Amundi as announced on 18 November 2025 (the “Strategic Partnership Announcement”).

Aggregated Information

Date of Purchase: Aggregate Number of Ordinary Shares Purchased: Lowest Price Paid per Ordinary Share (GBP): Highest Price Paid per Ordinary Share (GBP): Volume-Weighted Average Price Paid per Ordinary Share (GBP):
9 September 2026 72,916 1914.00 pence 1981.00 pence 1941.95 pence

The Ordinary Shares acquired were initially held in Treasury and subsequently cancelled.

Schedule of Purchases

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the “Market Abuse Regulation”), (as in force in the UK and as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019), a full breakdown of the individual trades made by BofA Securities on behalf of the Company as part of the programme is detailed on the attached:

ICG PLC Weekly Trade Fills

Completion of Share Buyback Programme

The Company confirms that, following the purchase of the Ordinary Shares disclosed above, the Share Buyback has now concluded. Since the commencement of the Share Buyback, the Company has repurchased 15,280,825 Ordinary Shares in aggregate at a weighted average price of 1790.56 pence per Ordinary Share for a total consideration of approximately £274 million. In accordance with the Subscription Agreement, Amundi has subscribed for an equivalent number of Ordinary Non-Voting shares. The subscription price for those Ordinary Non-Voting shares was equal to the repurchase price for the Ordinary Shares, and Amundi will reimburse the Company in cash for the costs and expenses incurred in connection with the Share Buyback.

As a result of the completion of the Share Buyback, Amundi has a 9.9% economic interest in the Company, including a 4.9% voting interest. The Ordinary Shares and Ordinary Non-Voting shares have the same economic entitlements, including as relates to dividends. Shareholders may therefore use the figure of 290,644,122 (being the combined number of Ordinary Shares and Non-Voting Ordinary shares outstanding) to assess their economic interest in the Company.

Cancellation of Treasury Shares and Total Voting Rights

The Company confirms that on 16 September 2026, following the completion of the Share Buyback, it cancelled 6,897,364 Ordinary Shares held in Treasury. Following the cancellation, the Company has 275,363,297 Ordinary Shares in issue and 15,280,825 Ordinary Non-Voting shares in issue.

Therefore, the total number of voting rights in the Company is 275,363,297, and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

No Ordinary Shares or Ordinary Non-Voting shares are currently held in Treasury.

Terms not defined here shall have the meaning as set out in the Strategic Partnership Announcement.

Enquiries:

Chris Hunt, Head of Corporate Development and Shareholder Relations, ICG
+44 (0) 20 3545 2020

Media:

Fiona Laffan, Global Head of Corporate Affairs, ICG
+44(0)20 3545 1510

Attachment

Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction

Oslo, 17 September 2026 – DNO ASA, the Norwegian oil and gas operator, announces that the boards of DNO, DNO Bidco AS and Capricorn Energy plc have agreed a revision to the terms of the Acquisition announced on 1 September 2026 pursuant to which Capricorn Shareholders will be entitled to receive an amount equal to the full Acquisition Value in cash from Bidco.

The boards of the three companies believe that the Revised All-Cash Offer provides Capricorn Shareholders with greater certainty of value as compared to the Original Offer, as it is not reliant on the Capricorn Board being able to declare and pay the Permitted Dividend in full prior to the Effective Date.

The Capricorn Directors intend to recommend unanimously that Capricorn Shareholders vote in favour of the Scheme at the Court Meeting and the resolutions to be proposed at the General Meeting, each to be convened as soon as practicable.

The full announcement is attached.

– 

For further information, please contact:
Media: media@dno.no
Investors: investor.relations@dno.no

– 

DNO ASA is a Norwegian oil and gas operator active in the North Sea and the Middle East. Founded in 1971, DNO is Norway’s oldest oil company and the first to list on the Oslo Stock Exchange in 1981. The Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in Norway, the Kurdistan region of Iraq, the United Kingdom and Yemen. More information is available at www.dno.no.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachment

ICG Enterprise Trust plc (the “Company”)

17 September 2026

Transaction in Own Shares

The Company announces that on 16 September 2026 it bought back 15,000 of its own shares under the long-term buyback programme, to be held as treasury shares, at an average price of 1408 pence per share.

Further details are set out below:

  • Number of shares held as treasury shares following settlement of this purchase: 3,194,951
  • Total shares in issue excluding treasury shares following settlement of this purchase: 60,359,241

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

Bang & Olufsen A/S has, pursuant to the Danish Capital Markets Act, received a major shareholder notification from UBS Group AG.

  • As per 11 September 2026, UBS Group AG’s holding of shares and voting rights pursuant to section 38 of the Danish Capital Markets Act, as well as other financial instruments pursuant to section 39(2), was below 5 percent of the total share capital and voting rights in Bang & Olufsen A/S.

As of 11 September 2026, UBS Group AG held a total of 7,347,988 shares and voting rights in Bang & Olufsen A/S, corresponding to 4.99 percent of the total share capital and voting rights.

For further information, please contact:

Cristina Rønde Hefting
Sr. Director, Head of Strategy & Investor Relations
Phone: +45 4153 7303

Attachment

COPENHAGEN, Denmark, September 17, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Tarja Stenvall has been appointed President and Chief Executive Officer, effective October 15, 2026, succeeding Paul Chaplin whose departure was announced earlier this year.

Tarja Stenvall is a global healthcare executive with over 20 years of leadership experience from Sanofi, AstraZeneca, and Pfizer, combining deep commercial expertise with a proven track record of building and transforming businesses at scale. She has held country, regional, and global roles across specialty care, general medicines, and vaccines, leading organizations of more than 3,000 people and having more than 3 billion euros profit-and-loss responsibility.

Chair of the Board of Directors, Anne Louise Eberhard, said: “Following a comprehensive search, the Board is pleased to appoint Tarja Stenvall as new Chief Executive Officer of Bavarian Nordic. Tarja Stenvall brings a proven ability to scale and lead a global life science business, combining strategic vision with deep experience from global pharma and vaccines industry and passion for improving and protecting lives. Bavarian Nordic is entering the next chapter from a position of strength. We have a clear purpose, and we will continue to scale our unique platform addressing infectious disease and improve the resilience of public health. The Board trusts Tarja to be the right profile to lead Bavarian Nordic. On behalf of the Board, I would also like to express our sincere appreciation to Paul Chaplin for his many years of dedicated leadership and profound impact on Bavarian Nordic. Under his leadership, the company evolved from a research-focused organization into a global vaccines company that today plays an important role in securing public health worldwide.”

Tarja Stenvall
said: “The opportunity to join Bavarian Nordic is tremendously exciting. What attracted me to Bavarian Nordic is its unique combination of a strong scientific foundation, a proven global manufacturing and supply chain and commercial platform. The company has built a leading position in vaccines while remaining firmly committed to improving and protecting lives, making this a truly compelling opportunity. Throughout my career in the life sciences and vaccine industry, I have been passionate about translating scientific innovation into meaningful patient impact by building global organizations and delivering long-term value and sustainable growth. I believe the company has a strong foundation for its next phase of growth, and I am excited by the opportunity to expand the global impact of Bavarian Nordic’s vaccines while continuing to strengthen the company’s position as a leading global vaccine company.”

Effective October 15, 2026, the Executive Management of Bavarian Nordic will consist of the following:

  • Tarja Stenvall, President & Chief Executive Officer
  • Henrik Juuel, EVP & Chief Financial Officer
  • Jean-Christophe May, EVP & Chief Commercial Officer
  • Russell Thirsk, EVP & Chief Operating Officer

About Tarja Stenvall
Tarja Stenvall is a senior pharmaceutical executive recognized for leading large-scale organizations across Europe, Latin America, and global markets. Throughout a career spanning more than two decades, she has held senior leadership positions at Sanofi, AstraZeneca, and Pfizer, building a reputation for driving sustainable growth, organizational transformation, and improved patient access to innovative medicines and vaccines.

She most recently served as Senior Vice President and Head of Global Franchise for diabetes and cardiovascular diseases at Sanofi, where she oversaw global portfolio strategy and long-term planning for a €10B franchise. Prior to this role, she held several senior leadership positions within Sanofi, including Senior Vice President for Key Markets in General Medicines, Senior Vice President for Europe, and Vice President for Vaccines in Latin America where she secured Sanofi’s largest global private-public partnership. During her tenure with Sanofi, she served as member of the Global Business Unit Leadership Team and the Global Sanofi Sustainability Impact Committee.

Prior to joining Sanofi in 2014, Tarja held various commercial leadership roles with increasing responsibility at AstraZeneca and has also held commercial leadership positions in Pfizer.

Tarja Stenvall holds a degree in Economics from Aalto University (formerly the Helsinki School of Economics and Business Administration) in Finland, and an MBA in International Business from the University of South Carolina in the US.

Images for the press are available on the company’s website:
https://www.bavarian-nordic.com/media/media/ceo.aspx

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel. +45 44 74 99 58
Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

Company Announcement no. 43 / 2026

This announcement contains publication of inside information pursuant to Article 17 of the EU Market Abuse Regulation.

Attachment

EXOSENS RAISES FULL-YEAR 2026 GUIDANCE, DRIVEN BY FASTER-THAN-EXPECTED CAPACITY RAMP-UP AND STRONG COMMERCIAL MOMENTUM

  • Faster-than-expected ramp-up of additional European production capacity for high-performance image intensifier tubes, meeting growing global demand for advanced night vision solutions sooner than anticipated
  • Accelerating adoption of mission-critical imaging technologies across drone, counter-drone and long-range surveillance applications
  • Strong momentum in nuclear instrumentation, driven by increasing demand for next-generation SMR technologies
  • 2026 guidance raised: c.20% revenue growth and c.25% adjusted EBITDA growth at midpoint vs. 2025, implying further profitability improvement
    • Revenue in the range of €558-570 million (vs. €520-540 million previously)
    • Adjusted EBITDA in the range of €186-192 million (vs. €168-178 million previously)

Press release, Mérignac (France), 17 September 2026 – Exosens (EXENS; FR001400Q9V2), a high-tech company focused on providing mission- and performance-critical amplification, detection and imaging technologies, today announces an upward revision to its full-year 2026 guidance.

This guidance upgrade builds on Exosens’ strong first-half 2026 performance and reflects sustained commercial momentum and continued disciplined execution driving industry-leading profitability.

In Amplification, Exosens maintained production throughout August at its European facilities for the first time, with the extended operating schedule implemented as planned. Newly installed production equipment was also successfully commissioned. These operational milestones have confirmed the faster-than-expected ramp-up of additional capacity for high-performance image intensifier tubes in Europe, enabling the Group to meet growing global demand for advanced night vision solutions sooner than anticipated.

In Detection & Imaging, Exosens continues to benefit from the accelerating adoption of its mission-critical imaging technologies across drone, counter-drone and long-range surveillance applications. To meet this growing customer demand, the Group is scaling its industrial capabilities, with plans to triple production capacity for thermal cameras and double capacity for cooled infrared cameras in 2026. Commercial momentum in nuclear instrumentation also remains strong, particularly in next-generation SMR applications.

Against this backdrop, Exosens is raising its full-year 2026 guidance and now expects:

  • Revenue in the range of €558 million to €570 million (compared with €520 million to €540 million previously);
  • Adjusted EBITDA in the range of €186 million to €192 million (compared with €168 million to €178 million previously);
  • Capital expenditure at around 9% of revenue (excluding capitalized R&D expenses of around 3% of revenue), driven by production capacity expansion in Europe and the U.S. (unchanged).

“Building on our strong first-half performance, we continue to see sustained commercial momentum across our markets. The faster-than-expected ramp-up of additional European production capacity for high-performance image intensifier tubes enables us to meet growing global demand for advanced night vision solutions sooner than anticipated. At the same time, our imaging technologies continue to gain traction, particularly across drone and surveillance applications, while demand in the nuclear market remains strong. This sustained momentum, combined with continued operational discipline, gives us confidence to raise our full-year 2026 guidance and supports our industry-leading profitability. Firmly focused on executing our strategy, we are well positioned to leverage our expanding industrial capabilities and recognized technology leadership to capture additional commercial opportunities and deliver sustained profitable growth over the long term,” said Jérôme Cerisier, CEO of Exosens.

Exosens will communicate its full-year 2027 guidance upon publication of the Group’s full-year 2026 results on 22 February 2027.

Financial calendar

  • 27/10/2026: 9M 2026 revenue and adjusted gross margin (before market opening).
  • 22/02/2027: FY 2026 results (before market opening).

About Exosens

Exosens is a high‐tech company, with more than 85 years of experience in the innovation, development, manufacturing and sale of high‐end electro‐optical technologies in the field of amplification, detection and imaging. Today, it offers its customers detection components and solutions such as advanced cameras, neutron and gamma detectors, instrument detectors and light intensifier tubes. This allows Exosens to respond to complex issues in extremely demanding environments by offering tailor-made solutions to its customers. Thanks to its sustained investments, Exosens is internationally recognized as a major innovator in optoelectronics, with production and R&D carried out on 13 sites, in Europe and North America, and with over 2,000 employees. Exosens is listed on compartment A of Euronext Paris regulated market (Ticker: EXENS; ISIN: FR001400Q9V2). Exosens is a member of Euronext Tech Leaders segment and is also included in several indices, including SBF 120, CAC All-Tradable, CAC Mid 60, FTSE Total Cap and MSCI France Small Cap. For more information: www.exosens.com.

Investor Relations

Laurent Sfaxi, l.sfaxi@exosens.com

Media Relations

Brunswick Group, exosens@brunswickgroup.com

Forward-looking statements

Certain information included in this press release is not historical fact but constitutes forward-looking statements. These forward-looking statements are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and the environment in which Exosens operates, and involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed in or implied by the forward-looking statements included in this press release. These risks and uncertainties include those set out and detailed in Chapter 4 “Risk factors and risk management system” of the Universal Registration Document filed on 9 March 2026 with the French financial markets authority (Autorité des marchés financiers – AMF) under number D.26-0072. Forward-looking statements speak only as of the date of this press release, and the Group expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements included in this press release to reflect any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Group. Actual results could differ materially from those expressed in, or implied or projected by, forward-looking information and statements. This press release is provided for information purposes only. It does not constitute, and should not be deemed to constitute, an offer to the public of securities.

Attachment

LA HULPE, BELGIUM – 17 September 2026, 7:00 a.m. CEST – Banqup Group SA (Euronext: BANQ) (Banqup, Company), a European fintech provider that simplifies financial flows through an innovative secured platform for e-invoicing, e-payment, e-reporting and e-trust solutions with built-in compliance at its core, today announced an operational and growth update on its footprint in the French market, timed with the 81st Congress of the Expert-Comptable Media Association (ECMA). Following years of regulatory delays across France, the official launch of the national e-invoicing mandate has triggered a significant growth in the number of users, proving the long-term strategic value of Banqup’s partner-led expansion model.

Partner-led blueprint delivers unprecedented scale

Banqup serves as the core technology provider behind jefacture.com, the accredited platform (Plateforme Agréée / PA) created by ECMA—the digital arm established by the French National Board of Chartered Accountants (CNOEC).

Rather than building costly direct sales networks, Banqup leveraged ECMA’s trusted distribution channel to embed its financial operating platform directly into the accounting ecosystem. Today, this channel strategy accounts for:

  • Almost 175,000 registered business clients, actively using the platform.
  • Nearly 4,900 chartered accounting firms, directing their client networks onto jefacture.com.

This partner-led Go-To-Market (GTM) playbook serves as the primary template Banqup is replicating across other key European growth markets facing mandatory e-invoicing transitions. Also, the onboarded network is an opportunity for upsell towards other products such as the payment module.

Management Commentary

“We have consistently communicated to our shareholders that the French market represented a major growth driver for Banqup,” said Koen De Brabander, CEO of Banqup Group. “While regulatory postponements delayed the initial timeline, the current adoption metrics prove that our patience and strategic execution is paying off. jefacture.com is now operating as a primary engine of automated financial workflows in France, validating our technology stack and our ability to monetize complex compliance shifts.”

Contact

David Geleyn
Head of Investor Relations – Banqup Group
investor.relations@banqup.com
media@banqup.com 

About ECMA & jefacture.com

Being a non-profit organisation created by the French National Council of the Order of Chartered Accountants, ECMA provides digital solutions simplifying and securing daily business of chartered accountants. ECMA supports French chartered accountants and their clients to their constant digital transformation. Among these solutions, jefacture.com is the e-invoicing platform designed by chartered accountants for their clients. jefacture.com is used on a daily basis by thousands of accounting firms and SMEs.

About Banqup Group

Banqup Group (Euronext Brussels: BANQ) architects the trust infrastructure needed to thrive in a digital-first economy. As a specialized European fintech provider and licensed payment institution, Banqup revolutionizes buying and selling for businesses and governments worldwide by digitalising financial supply chain processes within a secure, tax-compliant business network.

Moving beyond traditional software, Banqup operates a unified, open network platform that links business actors, accounting networks, banks, ERP systems, and tax authorities. Built around four interconnected pillars—e-invoicing, e-payments, e-reporting, and e-trust—Banqup enables digitisation of end-to-end order-to-cash and procure-to-pay workflows in full compliance with different regulatory frameworks.

Headquartered in Belgium with a history of pioneering digital transformation since 2001, Banqup is powering growth through effortless financial flows.

To learn more, visit www.banqup.com.

Cautionary note regarding forward-looking statements: The statements contained herein may include prospects, statements of future expectations, opinions, and other forward-looking statements in relation to the expected future performance of Banqup Group and the markets in which it is active. Such forward-looking statements are based on management’s current views and assumptions regarding future events. By nature, they involve known and unknown risks, uncertainties, and other factors that appear justified at the time at which they are made but may not turn out to be accurate. Actual results, performance or events may, therefore, differ materially from those expressed or implied in such forward-looking statements. Except as required by applicable law, Banqup Group does not undertake any obligation to update, clarify or correct any forward-looking statements contained in this press release in light of new information, future events or otherwise and disclaims any liability in respect hereto. The reader is cautioned not to place undue reliance on forward-looking statements.

Attachment

Wereldhave N.V. (‘Wereldhave’), through Wereldhave Belgium (70% owned by Wereldhave), announces the sale of retail park De Mael in Bruges (Belgium) to a consortium of private investors. The divestment of this non-core asset is in line with Wereldhave’s strategy to reduce leverage while focusing its portfolio on Full Service Centers.

Gross proceeds from the transaction amount to € 49.2 million, excluding transfer tax, reflecting a premium to the asset’s latest book value. Proceeds from the sale will further strengthen Wereldhave’s balance sheet, reducing the net loan-to-value (LTV) ratio by approximately 110bps compared with 30 June 2026. Transfer of the asset is scheduled for Q2 2027.

“This divestment reflects our disciplined approach to portfolio management. While our recent acquisitions in Belgium and Luxembourg have been made at net initial yields of 8%+, we have now sold De Mael at a 5.6% net initial yield. This accretive capital rotation strengthens our balance sheet while sharpening our focus on Full Service Centers.” said Matthijs Storm, CEO of Wereldhave.

Wereldhave was advised on the transaction by Avenue Real Estate.

About retail park De Mael
De Mael is a modern retail park in Bruges, Belgium, comprising approximately 20,000 m² GLA with excellent accessibility and a strong regional catchment area. Acquired by Wereldhave in 2018, the asset has undergone a comprehensive transformation programme into a future-proof retail destination anchored by a strong mix of retailers, including Albert Heijn XL, Dreamland, MediaMarkt, Brico, HEMA, Pearle, TUI and Medi-Market.

Attachment

  • Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment
  • Data reinforce the potential of this Lunsumio-based regimen to improve clinical outcomes, while offering a tolerable safety profile, simple dosing schedule and outpatient administration
  • Data will be submitted to health authorities and presented at an upcoming medical meeting

Basel, 17 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide versus MabThera®/Rituxan® (rituximab) plus lenalidomide in people with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one prior line of treatment met its primary endpoint. Results demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS). Overall survival (OS) data were immature at the time of interim analysis. The safety profile of the Lunsumio and lenalidomide combination was consistent with the known profiles of the individual study medicines, with no new safety signals identified. Data from the study will be submitted to health authorities and presented at an upcoming medical meeting.

“People living with relapsed or refractory follicular lymphoma need treatment options that provide meaningful clinical benefit and minimal disruptions to everyday care,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development.  “The CELESTIMO results indicate that a two-drug outpatient Lunsumio regimen may offer these patients an effective new option earlier in their treatment journey.”

CELESTIMO is a confirmatory study required to convert the accelerated approval/conditional marketing authorisation of Lunsumio monotherapy for third-line or later (3L+) FL to full approval, as well as to secure an indication in second-line or later (2L+) FL.

Lunsumio is part of Roche’s industry-leading CD20xCD3 bispecific antibody programme. It is designed with the unique needs and preferences of patients in mind, offering the possibility of outpatient treatment and flexibility between intravenous and subcutaneous administration routes. Lunsumio is already approved for people with 3L+ FL in 60 countries worldwide and has been used to treat over 3,800 patients.1

With the longest follow-up data of any bispecific antibody in lymphoma and a broad clinical development programme spanning multiple disease settings, including both FL and diffuse large B-cell lymphoma (DLBCL), Lunsumio is helping redefine care across B-cell malignancies. The U.S. Food and Drug Administration (FDA) recently accepted the supplemental Biologics License Application (sBLA) for Lunsumio in combination with Polivy® (polatuzumab vedotin) for 2L+ DLBCL based on the SUNMO study, and results from CELESTIMO support continued expansion of Lunsumio and lenalidomide into earlier FL treatment, with the phase III MorningLyte study ongoing in first-line FL.

About the CELESTIMO study
CELESTIMO [NCT04712097] is a phase III trial evaluating the efficacy and safety of Lunsumio® (mosunetuzumab) in combination with lenalidomide vs. MabThera®/Rituxan® (rituximab) plus lenalidomide in people with relapsed or refractory follicular lymphoma (FL) who have received at least one line of prior systemic therapy. It is a confirmatory study required to convert the accelerated approval/conditional marketing authorisation of Lunsumio monotherapy for third-line or later FL to full approval, as well as to secure an indication in second-line or later FL.

About follicular lymphoma
Follicular lymphoma (FL) is the most common slow-growing (indolent) form of non-Hodgkin lymphoma, accounting for about one in five cases.2 It typically responds well to treatment but is often characterised by periods of remission and relapse.3 The disease typically becomes harder to treat each time a patient relapses, and early progression can be associated with poor long-term prognosis.4 It is estimated that more than 110,000 people are diagnosed with FL each year worldwide.5

About Lunsumio® (mosunetuzumab)
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate malignant B cells. Lunsumio is currently approved as a fixed-duration monotherapy for the treatment of adult patients with third-line or later relapsed or refractory follicular lymphoma (FL) in both intravenous and subcutaneous (Lunsumio VELO™) formulations. A robust, global development programme is ongoing to explore the clinical utility of Lunsumio earlier in the disease course and in novel combinations, including the phase III CELESTIMO trial in second-line or later FL.

About Roche in haematology
Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3. Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Roche data on file.
[2] Lymphoma Research Foundation. About Follicular Lymphoma. [Internet; cited September 2026]. Available from: https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/follicular-lymphoma/
[3] Lymphoma Action. Follicular Lymphoma. [Internet; cited September 2026]. Available from: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/follicular-lymphoma
[4] Skarbnik AZ et al. Treatment selection for patients with relapsed or refractory follicular lymphoma. Front Oncol. 2023;13:1120358.
[5] World Health Organization. Numbers derived from GLOBOCAN 2022. Non-Hodgkin Lymphoma Factsheet [Internet; cited September 2026]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf.

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz
Phone: +41 79 529 70 35
Lorena Corfas
Phone: +41 79 568 24 95

 

Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83

 

Kirti Pandey
Phone: +41 79 398 38 53
Yvette Petillon
Phone: +41 79 961 92 50

 

Irène Stephan
Phone:  +41 79 377 83 75
Albert Thottiyil
Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

 

Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
 

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

 

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.